313 related articles for article (PubMed ID: 21795746)
1. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).
Mailankody S; Pfeiffer RM; Kristinsson SY; Korde N; Bjorkholm M; Goldin LR; Turesson I; Landgren O
Blood; 2011 Oct; 118(15):4086-92. PubMed ID: 21795746
[TBL] [Abstract][Full Text] [Related]
2. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
[TBL] [Abstract][Full Text] [Related]
3. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.
Castillo JJ; Gertz MA
Leuk Lymphoma; 2017 Apr; 58(4):773-780. PubMed ID: 27546465
[TBL] [Abstract][Full Text] [Related]
4. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Lenz G; Dreyling M; Schiegnitz E; Haferlach T; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2004 Dec; 22(24):4926-33. PubMed ID: 15611507
[TBL] [Abstract][Full Text] [Related]
5. Second malignancies after multiple myeloma: from 1960s to 2010s.
Thomas A; Mailankody S; Korde N; Kristinsson SY; Turesson I; Landgren O
Blood; 2012 Mar; 119(12):2731-7. PubMed ID: 22310913
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.
Yalniz FF; Greenbaum U; Pasvolsky O; Milton DR; Kanagal-Shamanna R; Ramdial J; Srour S; Mehta R; Alousi A; Popat UR; Nieto Y; Kebriaei P; Al-Atrash G; Oran B; Hosing C; Ahmed S; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
Transplant Cell Ther; 2024 Feb; 30(2):205.e1-205.e12. PubMed ID: 37437764
[TBL] [Abstract][Full Text] [Related]
7. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma.
Ge I; Saliba RM; Maadani F; Popat UR; Qazilbash MH; Ravi Pingali S; Shah N; Ahmed S; Bashir Q; Nieto Y; Champlin RE; Hosing C
Transfusion; 2017 Apr; 57(4):1052-1057. PubMed ID: 28185276
[TBL] [Abstract][Full Text] [Related]
8. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Koontz MZ; Horning SJ; Balise R; Greenberg PL; Rosenberg SA; Hoppe RT; Advani RH
J Clin Oncol; 2013 Feb; 31(5):592-8. PubMed ID: 23295809
[TBL] [Abstract][Full Text] [Related]
9. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
[TBL] [Abstract][Full Text] [Related]
10. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
Radivoyevitch T; Dean RM; Shaw BE; Brazauskas R; Tecca HR; Molenaar RJ; Battiwalla M; Savani BN; Flowers MED; Cooke KR; Hamilton BK; Kalaycio M; Maciejewski JP; Ahmed I; Akpek G; Bajel A; Buchbinder D; Cahn JY; D'Souza A; Daly A; DeFilipp Z; Ganguly S; Hamadani M; Hayashi RJ; Hematti P; Inamoto Y; Khera N; Kindwall-Keller T; Landau H; Lazarus H; Majhail NS; Marks DI; Olsson RF; Seo S; Steinberg A; William BM; Wirk B; Yared JA; Aljurf M; Abidi MH; Allewelt H; Beitinjaneh A; Cook R; Cornell RF; Fay JW; Hale G; Chakrabarty JH; Jodele S; Kasow KA; Mahindra A; Malone AK; Popat U; Rizzo JD; Schouten HC; Warwick AB; Wood WA; Sekeres MA; Litzow MR; Gale RP; Hashmi SK
Leuk Res; 2018 Nov; 74():130-136. PubMed ID: 30055822
[TBL] [Abstract][Full Text] [Related]
11. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
12. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.
Metayer C; Curtis RE; Vose J; Sobocinski KA; Horowitz MM; Bhatia S; Fay JW; Freytes CO; Goldstein SC; Herzig RH; Keating A; Miller CB; Nevill TJ; Pecora AL; Rizzo JD; Williams SF; Li CY; Travis LB; Weisdorf DJ
Blood; 2003 Mar; 101(5):2015-23. PubMed ID: 12393427
[TBL] [Abstract][Full Text] [Related]
14. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
Kaplan HG; Malmgren JA; Atwood MK
BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
[TBL] [Abstract][Full Text] [Related]
15. Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients.
Roeker LE; Larson DR; Kyle RA; Kumar S; Dispenzieri A; Rajkumar SV
Leukemia; 2013 Jun; 27(6):1391-3. PubMed ID: 23380709
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
Wang R; Zeidan AM; Yu JB; Soulos PR; Davidoff AJ; Gore SD; Huntington SF; Gross CP; Ma X
Prostate; 2017 Apr; 77(5):437-445. PubMed ID: 27868212
[TBL] [Abstract][Full Text] [Related]
17. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
18. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
[TBL] [Abstract][Full Text] [Related]
19. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
20. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
Kaplan HG; Malmgren JA; Li CI; Calip GS
Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
